A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Ovarian Neoplasms; Paresthesia; Breast Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT00746694

P05020

Details and patient eligibility

About

The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or therapeutic) for PPE and compliance of educational recommendations for PPE.

Enrollment: 154 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women 18 years of age or older.
• Participants with metastatic breast or ovarian cancer who are receiving treatment with pegylated liposomal doxorubicin.
• Participants who have given their written consent.

Exclusion criteria

• Participants who are currently participating in a clinical trial.

Trial design

154 participants in 1 patient group

Caelyx

Description:

Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.